AmpliMed Board, AmpliMed is a cancer research chemotherapy corporation with a drug class that features novel mechanisms of action that can defeat MDR and some toxicities

The Board of Directors.

The company has assembled an outstanding board of financiers, pharmaceutical executives and consultants to support and guide its activities.

Jock Holliman, Chairman of AmpliMed - Mr. Holliman has more than 20 years of experience in the venture capital industry in the southwestern United States. Following a career in corporate commercial banking with Bank of America and Chemical New York, Mr. Holliman joined Alliance Business Investment Company in Tulsa, Oklahoma in 1982. Three years later, Mr. Holliman accepted the newly created position as managing director of Valley National Bank of Arizona's venture capital program. From a $22 million capital base, Mr. Holliman oversaw 22 direct and three indirect investments in creating a successful portfolio. In early 1993, he formed Valley Ventures, L.P., a $10 million institutional secondary partnership, to purchase all venture capital assets from Valley Bank. Based upon the success of Valley Ventures, Mr. Holliman formed Valley Ventures II, L.P. closing at $29.4 million in April, 1999.

Jock Holliman holds undergraduate and graduate business degrees from Southern Methodist University in Dallas, as well as a master's degree in international management from the Thunderbird School of International Management in Phoenix, Arizona. Throughout his venture capital career, Mr. Holliman has been active in venture industry groups including NASBIC, the industry trade group in Washington, D.C. He served on its board of directors for five years through 1991, including two years on the executive committee. Mr. Holliman has served on 30 private and public company boards including Pilgrim American and OrthoLogic, notable Valley Ventures' winners.

Ronald Garren, M.D., Director - Dr. Garren is a board certified internist and has been practicing medicine for 30 years. He is a graduate of Harvard Medical School and completed his residency at New York Hospital. His clinical expertise is in the field of oncology. In 1991, he completed a three-year postdoctoral fellowship in molecular biology at Stanford in Dr. Paul Berg's lab. After finishing at Stanford, Dr. Garren has continued to practice hospital-based oncology as well as consult for biotech companies in the San Francisco Bay area. He has a founder equity position in Rigel Pharmaceuticals, Inc, a biotech company in South San Francisco. He is a partner in a small-cap biotech investment fund, Biotech Insight Management, and publishes a newsletter, Biotech Insight, for investors in small-cap biotech stocks.

Robert Dorr, Ph.D., CEO, AmpliMed Corporation - Dr. Dorr is a Professor of Pharmacology and Toxicology and is Director of the Pharmacology Program at the Arizona Cancer Center. He has expertise in the preclinical toxicology of anti-cancer and cancer preventative drugs. Dr. Dorr has served on many pharmaceutical company advisory boards. He has been founder or co-founder of three pharmaceutical companies, including AmpliMed, Clinuvel Ltd, and Paladin.

Harry George, Director - Mr. George is the Managing General Partner and co-founder of Solstice Capital, a venture capital fund investing in early-stage companies. Solstice Capital manages $80 million in two funds. Previously, Mr. George was the co-founder, VP of Finance and a Director of Interleaf, Inc., and an optical character recognition company later acquired by Xerox. Mr. George is currently a Director of a number of companies, including CellzDirect, High Throughput Genomics, Lumidigm, and Regenesis Biomedical. He graduated from Bowdoin College where he was a George S. Baker Scholar.

Joel Smolen, Director - Mr. Smolen is a business and financial consultant for Bay Area businesses, primarily in areas of asset preservation and strategic planning. In 1975 he founded Applied Molecular Technology Corporation (AMTEC), a Bay Area technology company specializing in technical metallurgical applications and technologies for the semi-conductor and aerospace industries. He remained as CEO until he sold AMTEC to a Swedish multinational corporation in 1982. He was founder and CEO of MicroMetallics Corporation (MICROMET) from 1972-1975, and was Senior Vice President of LMC Corporation from 1965-1972.

Mr. Smolen is the Managing Member of Biotech Insight Management, LLC, a California State Registered Investment Advisor. The Company manages a Hedge Fund “Biotech Insight Fund, LLP”. He is also the Managing General Partner of Biotech Insight Venture Partners a venture capital fund investing in early-stage bio medical companies.

Randolph Steer, M.D., Ph.D., Director - Dr. Steer has been an independent pharmaceutical, biotechnology and medical devices consultant since 1989. Dr. Steer has served as Associate Director of Medical Affairs at Marion Laboratories; Medical Director at Ciba Consumer Pharmaceuticals (Ciba-Geigy Corporation); Vice President, Senior Vice President and Member of the Executive Committee at Physicians World Communications Group; Chairman, President and Chief Executive Officer of Advanced Therapeutics Communications International, and Chief Executive Officer of Vicus.com, Inc. Dr. Steer is a member of the Board of Directors of Techne Corporation, BioCryst Pharmaceuticals and Vital Therapies Inc. He received his M.D. degree from the Mayo Medical School and his Ph.D. from the University of Minnesota.

Notice: AmpliMed® and Amplimexon® are registered trademarks of AmpliMed Corporation; Amplizone™ and Inspired Thinking - Advancing Cancer Research™ are trademarks of AmpliMed Corporation